Back to top
more

Pacira BioSciences (PCRX)

(Delayed Data from NSDQ)

$26.10 USD

26.10
621,147

-0.67 (-2.50%)

Updated Apr 18, 2024 04:00 PM ET

After-Market: $26.12 +0.02 (0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Pacira's (PCRX) Knee Osteoarthritis Drug Gets FDA's RMAT Tag

by Zacks Equity Research

Pacira (PCRX) receives the FDA's RMAT designation for its gene-therapy product candidate, PCRX-201, which is currently being developed in an early-stage study to treat osteoarthritis of the knee.

Pacira (PCRX) Q4 Earnings Match, Exparel Sales Drive Revenues

by Zacks Equity Research

Pacira (PCRX) reports fourth-quarter 2023 results, wherein earnings match and revenues beat estimates, driven by strong Exparel sales.

Here's What Key Metrics Tell Us About Pacira (PCRX) Q4 Earnings

by Zacks Equity Research

The headline numbers for Pacira (PCRX) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Pacira (PCRX) Matches Q4 Earnings Estimates

by Zacks Equity Research

Pacira (PCRX) delivered earnings and revenue surprises of 0% and 0.36%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Acadia Healthcare (ACHC) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Acadia Healthcare (ACHC) delivered earnings and revenue surprises of 6.25% and 1.90%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Ocular Therapeutix (OCUL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Ocular Therapeutix (OCUL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Countdown to Pacira (PCRX) Q4 Earnings: Wall Street Forecasts for Key Metrics

by Zacks Equity Research

Evaluate the expected performance of Pacira (PCRX) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Pacira (PCRX) Earnings Expected to Grow: What to Know Ahead of Q4 Release

by Zacks Equity Research

Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Pacira (PCRX) Preliminary '23 Revenues Solid, Exparel Strong

by Zacks Equity Research

Pacira (PCRX) posts preliminary revenues for the fourth quarter and full year 2023.

Pacira (PCRX) Gets FDA Nod for Exparel's Label Expansion

by Zacks Equity Research

The FDA approves Pacira's (PCRX) supplemental new drug application to expand the label of Exparel to include both sciatic and femoral nerve blocks.

Pacira (PCRX) Q3 Earnings and Revenues Miss, '23 View Updated

by Zacks Equity Research

Pacira (PCRX) announces weaker-than-expected third-quarter 2023 results. The company streamlines its 2023 guidance for net Exparel sales.

Pacira (PCRX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

Although the revenue and EPS for Pacira (PCRX) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Pacira (PCRX) Misses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Pacira (PCRX) delivered earnings and revenue surprises of -14.29% and 5.15%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Collegium Pharmaceutical (COLL) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Pacira (PCRX) to Report Q3 Results: Wall Street Expects Earnings Growth

by Zacks Equity Research

Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Pacira (PCRX) Down 8.9% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Pacira (PCRX) Q2 Earnings and Sales Miss, '23 View Updated

by Zacks Equity Research

Pacira (PCRX) announces weaker-than-expected second-quarter 2023 results. The company updates its 2023 financial guidance.

Compared to Estimates, Pacira (PCRX) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Pacira (PCRX) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Pacira (PCRX) Lags Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Pacira (PCRX) delivered earnings and revenue surprises of -3.70% and 3.51%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Pacira (PCRX) to Report Q2 Results: Wall Street Expects Earnings Growth

by Zacks Equity Research

Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Is Pacira (PCRX) Down 11.8% Since Last Earnings Report?

by Zacks Equity Research

Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Add Pacira (PCRX) Stock to Your Portfolio

by Zacks Equity Research

Pacira (PCRX) is witnessing strong growth on the back of its lead product, Exparel. Potential label expansion is set to boost sales in future quarters.

bluebird (BLUE) Posts Q1 Earnings, Focuses on Zynteglo, Skysona

by Zacks Equity Research

bluebird bio (BLUE) delivers earnings of 21 cents per share in the first quarter, due to a one-time gain. Revenues increase year over year.

Viatris (VTRS) Q1 Earnings Beat, Revenues Miss Estimates

by Zacks Equity Research

Viatris (VTRS) beats on Q1 earnings but misses sales. The company is now looking to reshape its business after selling its biosimilars portfolio.

Pacira (PCRX) Q1 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

Pacira (PCRX) misses on Q1 earnings but beats on revenues, even though volume growth of Exparel is offset by lower selling prices.